Quibim, with headquarters in Valencia, Spain, is a global leader in whole-body medical imaging analysis. Quibim products are used worldwide by leading research teams. Partners use Quibim PrecisionÂ®, a whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of novel treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers. We understand every body part. We speak human. In a world where patients still die because they get diagnosed too late or receive ineffective treatments, something needs to be done. We tackle this head on with Quibim PrecisionÂ®, the whole-body imaging ecosystem that understands every body part.
Find locations served, office locations
- Business Type:
- Service provider
- Industry Type:
- Clinical Services
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Discovering an anomaly in organs or tissues early is key to recovery, and preventative measures can delay disease onset altogether. Beyond diagnosis, imaging biomarkers also help us to better understand the mechanism of action of drug candidates and guide therapy, monitor recovery or relapse, and change the way research is being carried out.
We are on a mission to improve human health through AI-guided precision medicine and apply our advanced computational models to boost all fields from immuno-oncology to neurology. With Quibim, troves of clinical data typically hidden in imaging repositories and medical records emerge to guide clinicians, all over the world, every single day.
We established a step-by-step process for the development of novel imaging biomarkers. In 2013, the European Society of Radiology made it the reference industry guideline.
One of the many techniques we designed as early as 1994, soberly dubbed ‘temporal reconstruction images’, is now prevalent and known as Dynamic Contrast Enhanced MRI. It led to the discovery of permeability coefficients such as K-trans used in oncology to analyze tumor angiogenesis. It has since been linked to vascular endothelial growth factor in tissues.
As a global leader in whole-body medical imaging, we believe in evidence-based research. We publish extensively and have compiled one of the richest catalogues of imaging biomarkers and non-invasive detection methodologies in the world.
Our tools are used in daily practice and research to advance clinical knowledge.
Quibim was founded in 2012 by Dr. Luis Martí Bonmatí and Dr. Ángel Alberich Bayarri. It spun out from La Fe Health Research Institute, part of La Fe Polytechnics and University Hospital in Valencia, Spain.
Quibim continues to write the story of human health.
Quibim is a human story.